story of the week
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses From the BEACON Study
J. Clin. Oncol 2021 Feb 01;39(4)273-284, J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, J Desai, F Ciardiello, F Loupakis, YS Hong, N Steeghs, TK Guren, HT Arkenau, P Garcia-Alfonso, E Elez, A Gollerkeri, K Maharry, J Christy-Bittel, S KopetzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.